PDL BioPharma, Inc. announced unaudited consolidated earnings results for the two months and eight months ended August 31, 2020. For the period, the company announced total revenue of USD 4.115 million. Operating loss from continuing operations was USD 8.728 million. Net income was USD 4.384 million. Basic earnings per share was USD 0.04. Basic loss per share from continuing operations was USD 0.10. For the eight months, the company announced total revenue of USD 15.321 million. Operating loss from continuing operations was USD 54.250 million. Net loss was USD 77.955 million. Basic loss per share was USD 0.66. Basic loss per share from continuing operations was USD 0.36.